1 These biomarkers data begin to illuminate bortezomib 's mechanism of action in lymphoma.
2 Results: Thirty-one per cent of patients received bortezomib beyond first relapse.
3 However, apoptotic response to bortezomib was not affected by the deletion of p53.
4 Recently, it has been shown that bortezomib treatment enhances OB function.
5 The safety profile was consistent with that reported for single-agent bortezomib and romidepsin.
6 These data suggest that bortezomib - induced plasma cell depletion triggers humoral compensation.
7 We tested the signature in independent cohorts treated with bortezomib - and lenalidomide-based therapies.
8 After repeated treatment, initially sensitive lung tumors became resistant to bortezomib .
9 The synergistic interaction between oHSV and bortezomib was calculated using a Chou-Talalay analysis.
10 The combination of bortezomib and IFN-a can be safely administered to melanoma patients.
11 The proteasome inhibitor bortezomib is an efficacious apoptotic agent in many tumor cells.
12 The degree of proteasome inhibition was similar to that reported with single-agent bortezomib .
13 When possible, all subsequent doses of bortezomib within each cycle were provided at home.
14 Conversely, none of the patients who received a treatment without bortezomib developed muscular symptoms.
15 Conclusion: Both bortezomib plus rituximab regimens seem feasible in relapsed or refractory indolent lymphomas.
16 This delineates another therapeutic mechanism of bortezomib in T-cell malignancies.
Другие примеры для термина "bortezomib"
Grammar, pronunciation and more
Translations for bortezomib
Bortezomib в диалектах
Соединенные Штаты Америки